Literature DB >> 11875367

A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms.

Lori K Mattison1, Martin R Johnson, Robert B Diasio.   

Abstract

A pharmacogenetic syndrome caused by molecular defects in the dihydropyrimidine dehydrogenase gene (DPYD ) results in partial to complete loss of dihydropyrimidine dehydrogenase (DPD) enzyme activity with patients exhibiting life-threatening toxicity following administration of routine doses of 5-fluorouracil. To date, more than 19 reported mutations have been putatively associated with DPD deficiency with 16 occurring within the open reading frame of the cDNA. The purpose of this study was to examine the conservation of functional domains (including the uracil, flavine adenine dinucleotide and NADPH binding sites) across three phyla (Chordata, Arthropoda and Nematoda) and the conservation of regions corresponding to the previously reported mutations. Comparative analysis of the uracil and NADPH binding sites in mammals and invertebrates demonstrated 100% amino acid identity between mammals and Drosophila melanogaster. Caenorhabditis elegans demonstrated 89% and 88% identity in these domains, respectively. The mammalian sequences demonstrated 100% identity in two iron sulphur motifs (amino acids 953-964 and 986-997) with significant conservation in D. melanogaster (92% and 92% identity, respectively) and C. elegans (100% and 92% identity, respectively). Comparative amino acid analysis revealed non-conservation in the loci of four DPYD mutations [DPYD*12 (R21Q), DPYD*5 (I543V), DPYD*6 (V732I), DPYD*9A (C29R)]. Seven mutations occurred in highly conserved regions [M166V, DPYD*8 (R235W), DPYD*11 (V335l), DPYD*4 (S534N), DPYD*9B (R886H), D949V, DPYD*10 (V995F)]. In summary, this comparative analysis identified conserved regions which may be critical to enzyme structure and/or function. The conservation of loci where DPYD mutations occur was also examined to evaluate their functional significance on DPD enzyme activity. These data should prove useful in the evaluation of newly discovered mutations in the DPYD gene.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11875367     DOI: 10.1097/00008571-200203000-00007

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  9 in total

Review 1.  Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

2.  DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).

Authors:  Adam M Lee; Qian Shi; Emily Pavey; Steven R Alberts; Daniel J Sargent; Frank A Sinicrope; Jeffrey L Berenberg; Richard M Goldberg; Robert B Diasio
Journal:  J Natl Cancer Inst       Date:  2014-11-07       Impact factor: 13.506

3.  Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences.

Authors:  Keiko Maekawa; Mayumi Saeki; Yoshiro Saito; Shogo Ozawa; Kouichi Kurose; Nahoko Kaniwa; Manabu Kawamoto; Naoyuki Kamatani; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada; Kuniaki Shirao; Yasuhiro Shimada; Manabu Muto; Toshihiko Doi; Atsushi Ohtsu; Teruhiko Yoshida; Yasuhiro Matsumura; Nagahiro Saijo; Jun-Ichi Sawada
Journal:  J Hum Genet       Date:  2007-09-09       Impact factor: 3.172

4.  DPYD*5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients.

Authors:  Hong Zhang; You-ming Li; Hao Zhang; Xi Jin
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

5.  Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.

Authors:  A Ruzzo; F Graziano; Fabio Galli; Francesca Galli; E Rulli; S Lonardi; M Ronzoni; B Massidda; V Zagonel; N Pella; C Mucciarini; R Labianca; M T Ionta; I Bagaloni; E Veltri; P Sozzi; S Barni; V Ricci; L Foltran; M Nicolini; E Biondi; A Bramati; D Turci; S Lazzarelli; C Verusio; F Bergamo; A Sobrero; L Frontini; M Menghi; M Magnani
Journal:  Br J Cancer       Date:  2017-08-24       Impact factor: 7.640

6.  A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant.

Authors:  Vincenzo De Falco; Maria Iole Natalicchio; Stefania Napolitano; Nicola Coppola; Giovanni Conzo; Erika Martinelli; Nicoletta Zanaletti; Pasquale Vitale; Emilio Francesco Giunta; Maria Teresa Vietri; Pietro Paolo Vitiello; Davide Ciardiello; Anna Marinaccio; Ferdinando De Vita; Fortunato Ciardiello; Teresa Troiani
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

7.  Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients.

Authors:  Eva Gross; Birgit Busse; Matthias Riemenschneider; Steffi Neubauer; Katharina Seck; Hanns-Georg Klein; Marion Kiechle; Florian Lordick; Alfons Meindl
Journal:  PLoS One       Date:  2008-12-23       Impact factor: 3.240

Review 8.  SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand.

Authors:  Raffaele Palmirotta; Claudia Carella; Erica Silvestris; Mauro Cives; Stefania Luigia Stucci; Marco Tucci; Domenica Lovero; Franco Silvestris
Journal:  Oncotarget       Date:  2018-05-18

9.  Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients with Severe Fluoropyrimidine Toxicity: A Spanish Case-Control Study.

Authors:  Paula Soria-Chacartegui; Gonzalo Villapalos-García; Luis A López-Fernández; Marcos Navares-Gómez; Gina Mejía-Abril; Francisco Abad-Santos; Pablo Zubiaur
Journal:  Pharmaceutics       Date:  2021-11-29       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.